艾德生物(300685.SZ):與阿斯利康達成靶向藥物臨牀研究合作
格隆匯4月18日丨艾德生物(300685.SZ)公佈,近日,公司與AstraZeneca UK Limited (“阿斯利康”)簽署了兩份合作協議。分別為公司將與阿斯利康共同推進公司自主研發的伴隨診斷產品用於在中國、歐盟和日本識別具有同源重組修復(HRR)基因突變的前列腺癌患者的伴隨診斷註冊;公司將與阿斯利康共同推進公司自主研發的另一款伴隨診斷產品用於在歐洲地區識別具有BRCA突變的乳腺癌患者的伴隨診斷註冊。HRR和BRCA突變是已被充分證實的PARP抑制劑作用靶標,並且作為重要的生物標誌物,也可以為包括PARP抑制劑在內的其他潛在治療選擇提供信息。
公司聚焦腫瘤精準醫療領域,堅持創新、恪守合規,從TKIs靶向治療到PARPi藥物,再到免疫治療藥物,艾德生物均實現了伴隨診斷產品的前瞻性佈局和合規化應用,全面覆蓋肺癌、結直腸癌、乳腺癌、卵巢癌、前列腺癌等實體瘤及白血病的伴隨診斷需求。阿斯利康再次選擇公司作為其PARPi藥物在中國、歐盟和日本臨牀的伴隨診斷合作伙伴,是對艾德品牌和產品的信任和肯定,有利於進一步增強公司在腫瘤精準醫療市場的競爭力,對公司未來的發展將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.